Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

The MEST score provides earlier risk prediction in lgA nephropathy (CROSBI ID 229489)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Barbour SJ ; Espino-Hernandez G ; Reich HN ; Coppo R ; Roberts IS ; Feehally J ; Herzenberg AM ; Cattran DC ; Oxford Derivation, North American Validation and VALIGA Consortia ; Oxford Derivation North American Validation and VALIGA Consortia. The MEST score provides earlier risk prediction in lgA nephropathy // Kidney international, 89 (2016), 1; 167-175. doi: 10.1038/ki.2015.322

Podaci o odgovornosti

Barbour SJ ; Espino-Hernandez G ; Reich HN ; Coppo R ; Roberts IS ; Feehally J ; Herzenberg AM ; Cattran DC ; Oxford Derivation, North American Validation and VALIGA Consortia ; Oxford Derivation North American Validation and VALIGA Consortia.

engleski

The MEST score provides earlier risk prediction in lgA nephropathy

The Oxford Classification of IgA nephropathy (IgAN) includes the following four histologic components: mesangial (M) and endocapillary (E) hypercellularity, segmental sclerosis (S) and interstitial fibrosis/tubular atrophy (T). These combine to form the MEST score and are independently associated with renal outcome. Current prediction and risk stratification in IgAN requires clinical data over 2 years of follow-up. Using modern prediction tools, we examined whether combining MEST with cross- sectional clinical data at biopsy provides earlier risk prediction in IgAN than current best methods that use 2 years of follow-up data. We used a cohort of 901 adults with IgAN from the Oxford derivation and North American validation studies and the VALIGA study followed for a median of 5.6 years to analyze the primary outcome (50% decrease in eGFR or ESRD) using Cox regression models. Covariates of clinical data at biopsy (eGFR, proteinuria, MAP) with or without MEST, and then 2-year clinical data alone (2-year average of proteinuria/MAP, eGFR at biopsy) were considered. There was significant improvement in prediction by adding MEST to clinical data at biopsy. The combination predicted the outcome as well as the 2-year clinical data alone, with comparable calibration curves. This effect did not change in subgroups treated or not with RAS blockade or immunosuppression. Thus, combining the MEST score with cross-sectional clinical data at biopsy provides earlier risk prediction in IgAN than our current best methods.

IgA nephropathy ; glomerular disease ; renal pathology

Group Author(s): VALIGA Study (hrvatski suradnici: Krešimir Galešić i Danica Galešić-Ljubanović)

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

89 (1)

2016.

167-175

objavljeno

0085-2538

10.1038/ki.2015.322

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost